Screener
BioCryst Pharmaceuticals BCRX Increase (decrease) in cash, cash equivalents, and restricted cash
Increase (decrease) in cash, cash equivalents, and restricted cash at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed November 4, 2025.
- Filed
- Nov 4, 2025
- Fiscal quarter
- Q3 FY2025
- Calendar quarter
- Q3 2025
- Accession
- 0001628280-25-048785
| Line item | Nine Months Ended September 30, 2025 | Nine Months Ended September 30, 2024 |
|---|---|---|
| Principal payments on finance lease liabilities | (1,565) | (1,348) |
| Net cash used in financing activities | (131,971) | (1,740) |
| Effect of exchange rates on cash, cash equivalents and restricted cash | 1,342 | 368 |
| Decrease in cash, cash equivalents and restricted cash, including cash classified within current assets held for sale | (5,426) | (13,383) |
| Less: cash and cash equivalents classified within current assets held for sale | (14,840) | — |
| Net decrease in cash, and cash equivalents, and restricted cash | (20,266) | (13,383) |
| Cash, cash equivalents and restricted cash: | ||
| Beginning of period | 106,323 | 112,447 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's increase (decrease) in cash, cash equivalents, and restricted cash?
- BioCryst Pharmaceuticals (BCRX) reported increase (decrease) in cash, cash equivalents, and restricted cash of -$4.09M in Q3 2025.
- What does increase (decrease) in cash, cash equivalents, and restricted cash mean?
- Increase (decrease) in cash, cash equivalents, and restricted cash
Ask your AI about BioCryst Pharmaceuticals's increase (decrease) in cash, cash equivalents, and restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude